Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension Synhale Therapeutics has acquired Telaglenastat, a key move to enhance the company's clinical programs for pulmonary hypertension, targeting unmet patient needs.

Synhale Therapeutics Moves Forward with Acquisition of Telaglenastat for Treating Pulmonary Hypertension #None #Boston #Pulmonary_Hypertension #Synhale_Therapeutics #Telaglenastat